Rakuten Investment Management Inc. Makes New $437,000 Investment in Teva Pharmaceutical Industries Ltd. $TEVA

Rakuten Investment Management Inc. bought a new stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 21,617 shares of the company’s stock, valued at approximately $437,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of TEVA. AQR Capital Management LLC grew its stake in Teva Pharmaceutical Industries by 24.6% during the first quarter. AQR Capital Management LLC now owns 23,955 shares of the company’s stock valued at $368,000 after acquiring an additional 4,732 shares in the last quarter. Focus Partners Wealth boosted its holdings in Teva Pharmaceutical Industries by 4.5% in the 1st quarter. Focus Partners Wealth now owns 40,074 shares of the company’s stock valued at $616,000 after purchasing an additional 1,739 shares during the period. GAMMA Investing LLC grew its position in shares of Teva Pharmaceutical Industries by 65.9% during the 2nd quarter. GAMMA Investing LLC now owns 7,282 shares of the company’s stock valued at $122,000 after purchasing an additional 2,892 shares in the last quarter. Fifth Third Bancorp increased its holdings in shares of Teva Pharmaceutical Industries by 49.2% in the second quarter. Fifth Third Bancorp now owns 32,805 shares of the company’s stock worth $550,000 after purchasing an additional 10,820 shares during the period. Finally, Hartford Investment Management Co. raised its position in shares of Teva Pharmaceutical Industries by 30.9% in the second quarter. Hartford Investment Management Co. now owns 13,796 shares of the company’s stock worth $231,000 after buying an additional 3,257 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other news, VP Richard Daniell sold 115,468 shares of the company’s stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $28.68, for a total value of $3,311,622.24. Following the completion of the sale, the vice president owned 48,384 shares of the company’s stock, valued at approximately $1,387,653.12. This represents a 70.47% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Amir Weiss sold 12,300 shares of the stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $30.20, for a total transaction of $371,460.00. Following the transaction, the chief accounting officer directly owned 5,650 shares in the company, valued at approximately $170,630. This represents a 68.52% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 622,060 shares of company stock valued at $17,076,965. Insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Stock Performance

NYSE:TEVA opened at $31.83 on Monday. The company has a market capitalization of $36.51 billion, a price-to-earnings ratio of 53.05, a PEG ratio of 1.82 and a beta of 0.66. The business has a 50 day moving average of $29.64 and a 200 day moving average of $22.67. The company has a debt-to-equity ratio of 2.31, a current ratio of 1.11 and a quick ratio of 0.82. Teva Pharmaceutical Industries Ltd. has a 1-year low of $12.47 and a 1-year high of $33.42.

Wall Street Analyst Weigh In

Several equities analysts recently commented on TEVA shares. Weiss Ratings restated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday. Jefferies Financial Group lifted their price target on Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. Wall Street Zen lowered Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Sunday, January 18th. Scotiabank initiated coverage on shares of Teva Pharmaceutical Industries in a research note on Friday, December 5th. They issued a “sector outperform” rating and a $35.00 target price on the stock. Finally, Barclays began coverage on shares of Teva Pharmaceutical Industries in a research report on Tuesday, December 9th. They set an “overweight” rating and a $35.00 target price for the company. Three investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $33.67.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.